In patients with HF and T2DM, GLP-1 RA use was independently associated with more severe T2DM, reduced EF, and obesity and was not associated with a higher risk of HHF/CV death but with longer survival and less major CV adverse events. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.